Laboratory Medicine Program

Breast Cancer - (HR+/HER2- patients only)

Clinical Decription:
Genes within the phosphatidylinositol-3-kinase (PI3K) pathway can become mutated in breast and other cancers, leading to pathway activation that plays a key role in cancer cell proliferation and survival. In breast cancer, activating mutations in the PIK3CA gene is present in up to 40% of patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancers. Patient with advanced or metastatic breast cancer whose tumor tissue is HR-positive, HER2-negative and have PIK3CA mutations may benefit from treatment with PIK3CA inhibitors.

Method: Next-Generation Sequencing (NGS)

Component Tests Used: n/a

Reference Ranges Used:
Reference ranges for this test are not available online. However, they are included in all test results. For more information, please call us.

Specimen Type: Paraffin-embedded material (FFPE)/Cytology fluids
Volume: n/a

Shipping: room temperature or 4C

Special Instructions: Gene (PIK3CA) See requisitions for the full list of available testing and special instructions.

Testing Schedule(s): Please call

Turnaround Time: None

For more information, call 416.340.5227 or 1.866.865.5227